Author(s): Joysa Ruby Joseph, Venkatesh Dinneker Puttegowda, Selvakumar Kanthiah, Ajay Pankajbhai Lunagariya, Jeevan Kumar Mishra, Ashly Merin George

Email(s): joysarubyj@acharya.ac.in , joysaruby2010@gmail.com

DOI: 10.52711/0974-360X.2025.00008   

Address: Joysa Ruby Joseph1*, Venkatesh Dinneker Puttegowda2, Selvakumar Kanthiah3, Ajay Pankajbhai Lunagariya4, Jeevan Kumar Mishra5, Ashly Merin George6
1,2,4,5,6Department of Pharmaceutics, Acharya and BM Reddy College of Pharmacy, Rajiv Gandhi University of Health Sciences, Bangalore 560107, Karnataka, India.
3Department of Pharmaceutical Quality Assurance, Acharya and BM Reddy College of Pharmacy, Rajiv Gandhi University of Health Sciences, Bangalore 560107, Karnataka, India.
*Corresponding Author

Published In:   Volume - 18,      Issue - 1,     Year - 2025


ABSTRACT:
Headache serves as a prevalent symptom across various diseases and disorders, with migraines notably exerting a substantial impact on an individual's daily well-being and occupational functionality. Immediate management of migraines assumes pivotal significance due to the prolonged and debilitating nature of associated symptoms. Migraines commonly manifest in two forms: migraine with aura and migraine without aura. Afflicted individuals often contend with enduring symptoms such as phonophobia, photophobia, and manifestations akin to vomiting. Traditional medications necessitate a protracted timeframe, often exceeding 1-2 hours, for alleviating pain induced by migraines. The innovative approach of nose-to-brain drug delivery emerges as a promising strategy in addressing neurological conditions, offering the advantage of mitigating undesired side effects compared to conventional pharmaceutical interventions. By specifically targeting the olfactory and trigeminal nerves, this method circumvents the Blood-Brain-Barrier (BBB), thereby yielding more favorable therapeutic outcomes. Although diverse nano formulations have been developed, the concept of nano inhalable dry powder stands out as an optimal modality for migraine treatment. This comprehensive review encapsulates the existing pharmacotherapeutic landscape for migraine treatment, delving into the diverse modalities employed in the development of dry powder formulations, elucidating their inherent advantages, and contemplating the future trajectory of nano-inhalable dry powder applications in migraine therapeutics.


Cite this article:
Joysa Ruby Joseph, Venkatesh Dinneker Puttegowda, Selvakumar Kanthiah, Ajay Pankajbhai Lunagariya, Jeevan Kumar Mishra, Ashly Merin George. Recent development of Nose-to-Brain delivery as inhalable dry nanoparticles for the treatment of Migraine. Research Journal of Pharmacy and Technology. 2025;18(1):51-7. doi: 10.52711/0974-360X.2025.00008

Cite(Electronic):
Joysa Ruby Joseph, Venkatesh Dinneker Puttegowda, Selvakumar Kanthiah, Ajay Pankajbhai Lunagariya, Jeevan Kumar Mishra, Ashly Merin George. Recent development of Nose-to-Brain delivery as inhalable dry nanoparticles for the treatment of Migraine. Research Journal of Pharmacy and Technology. 2025;18(1):51-7. doi: 10.52711/0974-360X.2025.00008   Available on: https://rjptonline.org/AbstractView.aspx?PID=2025-18-1-8


REFERENCES:
1.    Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of Migraine: A Disorder of Sensory Processing. Physiological Reviews. 2017; Apr 1; 97(2): 553-622. doi: 10.1152/physrev.00034.2015
2.    Olesen J, Bes A, Kunkel R, Lance JW, Nappi G, Pfaffenrath V. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013; Jun 14; 33(9): 629-808. doi: 10.1177/0333102413485658
3.    Vyas TK, Babbar AK, Sharma RK, Singh S, Misra A. Preliminary Brain-targeting Studies on Intranasal Mucoadhesive Microemulsions of Sumatriptan. AAPS PharmSciTech. 2006 Mar 8; 7(1): E49-E57. doi: 10.1208/pt070108
4.    Weatherall MW. The diagnosis and treatment of chronic migraine. Ther Adv Chronic Dis. 2015; Apr 5; 6(3): 115–23. doi: 10.1177/2040622315579627
5.    Meng W, Adams MJ, Hebert HL, Deary IJ, McIntosh AM, Smith BH. A Genome-Wide Association Study Finds Genetic Associations with Broadly-Defined Headache in UK Biobank (N = 223,773). Ebio Medicine. 2018; Feb 1; 28: 180–6. doi:10.1016/j.ebiom.2018.01.023
6.    Mauskop A, Varughese J. Why all migraine patients should be treated with magnesium. J Neural Transm. 2012; Mar 18; 119(5): 575–9. doi: 10.1007/s00702-012-0790-2
7.    Dolati S, Rikhtegar R, Mehdizadeh A, Yousefi M. The Role of Magnesium in Pathophysiology and Migraine Treatment. Biol Trace Elem Res. 2019; Nov 5; 196(2): 375-83. doi: 10.1007/s12011-019-01931-z
8.    Blakely KK, Stallworth K. Lasmiditan Is a New Option for Acute Migraine Treatment. Nurs Womens Health. 2020 Aug 1;24(4):294-9. doi: 10.1016/j.nwh.2020.05.008
9.    Negro A, Martelletti P. Gepants for the treatment of migraine. Expert Opin Investig Drugs. 2019; May 17; 28(6): 555-567. doi: 10.1080/13543784.2019.1618830
10.    Spuntarelli V, Negro A, Luciani M, Bentivegna E, Martelletti P. Eptinezumab for the treatment of migraine. Expert Opin Biol Ther. 2021; Jun 1; 21(8): 999-1011. doi: 10.1080/14712598.2021.1931678
11.    U. Viplava Prasad, Manukonda Syam Bab, Buridi Kalyana Ramu. Visible Spectrophotometric Assay of Almotriptan Malate using Ion-association Methods. Research J. Pharm. and Tech. 2012; 5(8): August 1107-1111.
12.    A. Elphine Prabahar, R. Kalaichelvi, B. Thangabalan, R. Karthikeyan, Ch. Prabhakar, P. Vijayaraj Kumar. Validated Spectroscopic Method for Estimation of Sumatriptan succinate in Pure and from Tablet Formulation. Research J. Pharm. and Tech. 2009; 2 (3): July-Sept. 495-497.
13.    Feigin VL, Krishnamurthi RV, Theadom AM, Abajobir AA, Mishra SR, Ahmed MB, et al. Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol. 2017; Nov 1; 16(11): 877-97. doi: 10.1016/S1474-4422(17)30299-5
14.    Swati Patni. Comprehensive Review of Medicinal plants used in treatment of Migraine. Asian J. Res. Pharm. Sci. 2020; 10(3):189-194. doi: 10.5958/2231-5659.2020.00036.3
15.    Sunena, Sumit Kumar, Sulekha, Deepali Tomar, Dinesh Kumar, Vimal Kishore. Applications of Polymeric Nanoparticle in Nose to Brain Drug Delivery. Research Journal of Pharmacy and Technology. 2023; 16(12): 6087-4. doi: 10.52711/0974-360X.2023.00988
16.    Marttin E, Schipper NGM, Verhoef JC, Merkus FW. Nasal mucociliary clearance as a factor in nasal drug delivery. Adv Drug Deliv Rev. 1998; Jan 5; 29(1-2): 13-38. doi: 10.1016/s0169-409x(97)00059-8
17.    Mittal D, Ali A, Md S, Baboota S, Sahni JK, Ali J. Insights into direct nose to brain delivery: Current status and future perspective. Drug Deliv. 2014; Mar 1; 21(2): 75-86. doi: 10.3109/10717544.2013.838713
18.    Trapani A, Cometa S, de Giglio E, Corbo F, Cassano R, di Gioia ML, et al. Novel Nanoparticles Based on N,O- Carboxymethyl Chitosan-Dopamine Amide Conjugate for Nose-to-Brain Delivery. Pharmaceutics. 2022; Jan 8; 14(1): 147-69. doi: 10.3390/pharmaceutics14010147
19.    Merin. T. Koshy, Lincy Joseph. A Prospective Study of Propranolol and Flunarizine in the Prophylactic Therapy of Migraine in a Tertiary Care Hospital. Research J. Pharm. and Tech 2020; 13(5): 2159-2162. doi: 10.5958/0974-360X.2020.00388.1
20.    Agrawal M, Saraf S, Saraf S, Antimisiaris SG, Chougule MB, Shoyele SA, et al. Nose-to-brain drug delivery:An update on clinical challenges and progress towards approval of anti-Alzheimer drugs. Journal of Controlled Release. 2018; Jul 10: 281: 139-77. doi: 10.1016/j.jconrel.2018.05.011
21.    Masjedi M, Azadi A, Heidari R, Mohammadi-Samani S. Brain targeted delivery of sumatriptan succinate loaded chitosan nanoparticles: Preparation, In vitro characterization, and (Neuro)pharmacokinetic evaluations. J Drug Deliv Sci Technol. 2021; Feb 1; 61: 102179. doi:10.1016/j.jddst.2020.102179
22.    Ajina C T, Narayana Charyulu R, Sandeep D S. Rizatriptan Transdermal Patches for the Treatment of Migraine. Research J. Pharm. and Tech. 2018; 11(3): 873-878. doi: 10.5958/0974-360X.2018.00162.2
23.    Singh A, Ubrane R, Prasad P, Ramteke S. Preparation and Characterization of Rizatriptan Benzoate Loaded Solid Lipid Nanoparticles for Brain Targeting. Mater Today Proc. 2015; Jan 1; 2(9): 4521–43. doi: 10.1016/j.matpr.2015.10.067
24.    Papi A, Haughney J, Virchow JC, Roche N, Palkonen S, Price D. Inhaler devices for asthma: A call for action in a neglected field. European Respiratory Journal. 2011; May 1; 37(5): 982-5. doi: 10.1183/09031936.00150910
25.    Tiozzo Fasiolo L, Manniello MD, Tratta E, Buttini F, Rossi A, Sonvico F, et al. Opportunity and challenges of nasal powders: Drug formulation and delivery. Eur J Pharm Sci. 2018; Feb 15: 113: 2-17. doi: 10.1016/j.ejps.2017.09.027
26.    Surendiran A, Sandhiya S, Pradhan SC, Adithan C. Novel applications of nanotechnology in medicine. Indian Journal of Medical Research. 2009; Dec 1; 130(6): 689-701.
27.    Wajid Ahmad, Rihan Jawed. Formulation and Evaluation of Chewable Oral Jelly containing Zolmitriptan hydrochloride. Research Journal of Pharmaceutical Dosage Forms and Technology. 2022; 14(2): 139-4. doi: 10.52711/0975-4377.2022.00022
28.    Battaglia L, Panciani PP, Muntoni E, Capucchio MT, Biasibetti E, de Bonis P. Lipid nanoparticles for intranasal administration: application to nose-to-brain delivery. Expert Opin Drug Deliv. 2018; Apr 3; 15(4): 369-378. doi: 10.1080/17425247.2018.1429401
29.    Chaurasiya B, Zhao YY. Dry Powder for Pulmonary Delivery: A Comprehensive Review. Pharmaceutics. 2020; Dec 28; 13(1): 31. doi: 10.3390/pharmaceutics13010031
30.    Swati Lade, Nirmal Shah, Sushil Burle. Nanostructured Lipid Carriers: A Vital Drug Carrier for Migraine Treatment. Research Journal of Pharmacy and Technology. 2022; 15(7): 3309-6. doi: 10.52711/0974-360X.2022.00554
31.    Dalpiaz A, Fogagnolo M, Ferraro L, Capuzzo A, Pavan B, Rassu G, et al. Nasal chitosan microparticles target a zidovudine prodrug to brain HIV sanctuaries. Antiviral Res. 2015; Nov 1: 123: 146-57. doi: 10.1016/j.antiviral.2015.09.013
32.    Karpel JP. An easy-to-use dry-powder inhaler. Adv Ther. 2000; Nov 1; 17(6): 282-6. doi: 10.1007/BF02850011
33.    Spandana B, Shashidher B, Dinesh S, Nagaraj B. Eletriptan hydrobromide Orodispersible tablets: Design, Development and In vitro characterization. Research J. Pharm. and Tech. 2020; 13(11): 5339-5344. doi: 10.5958/0974-360X.2020.00933.6
34.    Abd El-Aziz B. Abd El-Aleem, Shaban M. Khalile, Amr M. Badawy, Omneya K. El-Naggar. HPLC and TLC-Densitometric Methods for the Determination of some Antimigraine Drugs in Bulk Powder and in Pharmaceutical Preparations. Research J. Pharma. Dosage Forms and Tech. 2013; 5(5): 288-294.
35.    Tepper SJ, Johnstone MR. Breath-powered sumatriptan dry nasal powder: An intranasal medication delivery system for acute treatment of migraine. Med Devices (Auckl). 2018; May 3: 11: 147-156. doi: 10.2147/MDER.S130900
36.    Sahakijpijarn S, Moon C, Ma X, Su Y, Koleng JJ, Dolocan A, et al. Using thin film freezing to minimize excipients in inhalable tacrolimus dry powder formulations. Int J Pharm. 2020; Aug 30: 586: 119490. doi: 10.1016/j.ijpharm.2020.119490
37.    Buridi Kalyana Ramu, K. Raghubabu. Extractive Visible Spectrophotometric Assay for Sumatriptan Succinate Estimation Based on Ion-Association Complex Formation. Research J. Pharm. and Tech. 2011; 4(8): Aug. 1212-1215.
38.    Ristroph KD, Feng J, McManus SA, Zhang Y, Gong K, Ramachandruni H, et al. Spray drying OZ439 nanoparticles to form stable, water-dispersible powders for oral malaria therapy. J Transl Med. 2019; Mar 22; 17(1): 1-12. doi: 10.1186/s12967-019-1849-8
39.    Vo CLN, Park C, Lee BJ. Current trends and future perspectives of solid dispersions containing poorly Water- soluble drugs. Eur J Pharm Biopharm. 2013; Nov. 1; 85(3): 799-813. doi: 10.1016/j.ejpb.2013.09.007
40.    Jaworek A, Sobczyk AT, Krupa A. Electrospray application to powder production and surface coating. J Aerosol Sci. 2018; Nov 1; 125: 57–92. doi: 10.1016/j.jaerosci.2018.04.006
41.    Soares RMD, Siqueira NM, Prabhakaram MP, Ramakrishna S. Electrospinning and electrospray of bio-based and natural polymers for biomaterials development. Materials Science and Engineering C. 2018; Nov 1; 92: 969–82. doi: 10.1016/j.msec.2018.08.004
42.    Clément Rigaut, Laura Deruyver, Jonathan Goole, Benoît Haut , Pierre Lambert . Instillation of a Dry Powder in Nasal Casts: Parameters Influencing the Olfactory Deposition with Uni- and Bi-Directional Devices Front. Front Med Technol. 2022; Jun 27: 4: 924501. doi: 10.3389/fmedt.2022.924501
43.    Nodilo LN, Ugrina I, Spoljarić D, Klarić DA, Brala CJ, Perkušić M, et al. A dry powder platform for nose-to- brain delivery of dexamethasone: Formulation development and nasal deposition studies. Pharmaceutics. 2021; May 26; 13(6): 795. doi: 10.3390/pharmaceutics13060795
44.    Nigam K, Kaur A, Tyagi A, Nematullah M, Khan F, Gabrani R, et al. Nose-to-brain delivery of lamotrigine-loaded PLGA nanoparticles. Drug Deliv Transl Res. 2019; Mar 18; 9(5): 879-890. doi: 10.1007/s13346-019-00622-5
45.    Couvreur P, et al. Evaluation of brain-targeted chitosan nanoparticles through blood–brain barrier Cerebral microvessel endothelial cells. J Microencapsul 2017; Sep 13; 34(7): 659-666. doi: 10.1080/02652048.2017.1375039
46.    Aderibigbe BA, Naki T. Chitosan-based nanocarriers for nose to brain delivery. Applied sciences. 2019; May 30; 9(11): 2219. doi:10.3390/app9112219

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

1.3
2021CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank

Journal Policies & Information


Recent Articles




Tags


Not Available